Research
Hormonal
Liraglutide (GLP-1 analogue) barely met the primary endpoint for NASH resolution in a small trial, while Sitagliptin showed no effect on liver histology.
GLP-1 therapies like Liraglutide show marginal benefit for NASH resolution, while others like Sitagliptin show no histological benefit. They are not primary treatments.
ModerateQualifiesMEDIUM confidence
The GLP-1 analogue liraglutide... barely met the primary endpoint of resolution of NASH without fibrosis (9/23 vs 8/22 placebo treated patients, P 0.019). In a study of sitagliptin... the drug was not found to have any effect on liver histology or ALT in patients with NASH [44].
Why this rating
Mixed results between Liraglutide (barely significant) and Sitagliptin (negative).
Source
Non-alcoholic fatty liver disease
Brent A. Neuschwander‐Tetri · BMC Medicine · 2017
DOI 10.1186/s12916-017-0806-8
narrative_reviewCited 462×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Lifestyle modification focusing on weight loss and exercise is the primary effective therapy for reversing features of non-alcoholic steatohepatitis (NASH) and fibrosis.Good
- Pioglitazone and Vitamin E are beneficial pharmacological interventions for non-diabetic NASH patients, and Pioglitazone improves fibrosis in diabetic patients.Good
- Elafibranor (PPAR alpha/delta agonist) and Obeticholic Acid (FXR ligand) show promise in resolving NASH and improving fibrosis in clinical trials.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →